Ann: Appendix 4C and Quarterly Update, page-2

1. Successful completion of Phase 1 MND Study, with positive safety and preliminary efficacy results. The Safety Monitoring Committee recommended escalating to the next and final dose level, with top-line results expected in Q1CY2024.
2. Continued promising results in the Phase 2 canine cancer study using monepantel (MPL).
3. Dr. Michael Thurn, PhD, was appointed as Chief Executive Officer.
4. The company had a cash position of approximately $1.7 million at the end of the quarter, with an additional $1.1 million expected to be received by the end of 2023.
5. The company intends to apply for FDA Orphan Drug Designation for its MND/ALS treatment.
6. The Phase 2 study for B-Cell Lymphoma in dogs showed encouraging results, extending survival and maintaining a high quality of life for the animals.
7. The company announced the voluntary liquidation of its subsidiary Epichem, focusing on the clinical development of MPL.
8. PharmAust is actively engaging in PR and marketing activities to increase market awareness.
9. The Appendix 4C Quarterly Cash Flow Report indicates a cash position of $1.725 million as of September 30, 2023, with additional funding expected from various sources.